Safety and Efficacy of Bone Marrow Cell Transplantation in Humans Myocardial Infarction
NCT ID: NCT00437710
Last Updated: 2010-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
50 participants
INTERVENTIONAL
2005-07-31
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
After standard therapy for acute MI, 10 patients were transplanted with autologous mononuclear BMCs via a balloon catheter placed into the infarct-related artery during balloon dilatation (percutaneous transluminal coronary angioplasty). Another 10 patients with acute MI were treated by standard therapy alone. After
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Transplantation to Treat Heart Diseases
NCT01234181
Treatment of Myocardial Infarction With Bone Marrow Derived Stem Cells
NCT00275977
Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.
NCT02033278
Intracoronary Infusion of Bone Marrow Mononuclear Cells in Patients With Previous Myocardial Infarction.
NCT01454323
Bone Marrow-Derived Stem Cell Transfer in Acute Myocardial Infarctions
NCT00264316
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cell therapy, bone marrow derived stem cell
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* single left anterior descending coronary artery disease
* \<72 hour from the origin of symptoms
* successful primary angioplasty of the culprit lesion
Exclusion Criteria
* cardiac shock, severe comorbidity, alcohol or drug dependency
* severe comorbidity (DM,renal or liver insufficiency)
* potential child bearing woman
* inability to provide informed consent
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Unita Sanitaria Locale di Piacenza
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Massimo Piepoli, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
G. da Saliceto Hospital, Regional Health Authority
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
G da Saliceto Hospital
Piacenza, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Azienda USL Piacenza web site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01/2007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.